Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. - Goldberg, Sarah B; Schalper, Kurt A; Gettinger, Scott N; Mahajan, Amit; Herbst, Roy S; Chiang, Anne C; Lilenbaum, Rogerio; Wilson, Frederick H; Omay, Sacit Bulent; Yu, James B; Jilaveanu, Lucia; Tran, Thuy; et al. (Lancet Oncology, 2020)